PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.\', \'Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK christopher.butler@phc.ox.ac.uk.\', \'Berry Consultants, Austin, Texas, USA.\', \'Department of Biostatistics, Vanderbilt University School of Medicine, Nashville, Tennessee, USA.\', \'Centre for the Aids Programme of Research in South Africa, Durban, South Africa.\', \'Department of Clinical and Experimental Medicine, University of Surrey, Guildford, UK.\', \'Windrush Medical Practice, Witney, UK.\', \'Royal College of General Practitioners, London, UK.\', \'St Leonard\'s Research Practice, Exeter, UK.\', \'University of Exeter Medical School, Exeter, UK.\', \'Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.\', \'Department of Microbiology and Infection, University Hospitals Sussex NHS Foundation Trust, Brighton, UK.\', \'Department of Global Health and Infection, Brighton and Sussex Medical School, Brighton, UK.\', \'Public Health England, London, UK.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1136/bmjopen-2020-046799
?:doi
?:hasPublicationType
?:journal
  • BMJ open
is ?:pmid of
?:pmid
?:pmid
  • 34145016
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.372
?:rankingScore_hIndex
  • 57
?:title
  • Platform Randomised trial of INterventions against COVID-19 In older peoPLE (PRINCIPLE): protocol for a randomised, controlled, open-label, adaptive platform, trial of community treatment of COVID-19 syndromic illness in people at higher risk.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all